Form 8-K · Current report
Fortive 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0001659166
- Accession no.
- 0001659166-26-000033
Summary
Fortive reported second-quarter 2026 revenue of $1.10 billion, up 7.9% year-over-year, with GAAP diluted EPS of $0.51 and adjusted diluted EPS of $0.74, and raised its full-year 2026 adjusted EPS guidance to $2.95–$3.05. CEO Olumide Soroye attributed the results to core revenue growth of 6.7% and about $200 million of share repurchases in the quarter under the company's Fortive Accelerated strategy.
Key points
- Q2 2026 revenue was $1.10 billion, up 7.9% year-over-year reported and 6.7% core; GAAP diluted EPS was $0.51 and adjusted diluted EPS $0.74.
- Fortive repurchased about $200 million of shares in Q2, bringing the last four quarters to roughly $2 billion, about 38 million shares or 11% of shares outstanding.
- Full-year 2026 adjusted EPS guidance was raised to $2.95–$3.05.
- The quarter followed the June 28, 2025 separation of the former Precision Technologies segment into Ralliant Corporation, with Ralliant reported as discontinued operations.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On July 29, 2026, Fortive Corporation (the "Company") issued a press release announcing financial results for the quarter ended July 3, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information set forth in this Item 2.02 of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 are being furnished pursuant to Item 2.02 of Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.